Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for Cytomegalovirus prophylaxis in organ transplants, VARIZIG for varicella post-exposure prophylaxis, WINRHO SDF for immune thrombocytopenic purpura and rhesus isoimmunization suppression, HEPAGAM B for hepatitis B prevention in liver transplants and post-exposure, GLASSIA for intravenous AATD, KAMRHO (D) IM for hemolytic disease of newborns prophylaxis, and Echis coloratus and Vipera palaestinae Antiserum for snake bite treatment. The company also distributes biopharmaceutical products in Israel, including BRAMITOB, FOSTER, TRIMBOW, PROVOCHOLINE, AEROBIKA, RUPAFIN and RUPAFIN ORAL SOLUTION, SINTREDIUS, IVIG, VARITECT, ZUTECTRA and HEPATECT CP, MEGALOTECT CP, RUCONEST, HEPARIN SODIUM INJECTION, ALBUMIN and ALBUMIN for blood plasma, Factor VIII, Factor IX, COAGADEX, IXIARO, VIVOTIF, PROCYSBI, LAMZEDE, RYPLAZIM, ELIGARD, and BEVACIZUMAB KAMADA. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.